StockData
MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc. (INKT) stock

INKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$8.02−0.59 (-6.85%)

Close on Nov 20, 2026Market cap $40.93MP/E –Yield –

MiNK Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

MiNK Therapeutics's free cash flow for the twelve months ending Dec 31, 2023 was -$15.84M. For fiscal 2023 it was -$15.84M.

Annual free cash flow

PeriodPeriod endValueChange
FY2023Dec 31, 2023-$15.84M–
FY2022Dec 31, 2022-$19.12M–
FY2021Dec 31, 2021-$13.08M–
FY2020Dec 31, 2020-$8.43M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023-$3.04M–
Q3 FY2023Sep 30, 2023-$4.23M–
Q2 FY2023Jun 30, 2023-$4.19M–
Q1 FY2023Mar 31, 2023-$4.38M–
Q4 FY2022Dec 31, 2022-$4.56M–
Q3 FY2022Sep 30, 2022-$5.67M–
Q4 FY2021Dec 31, 2021-$1.70M–
Q3 FY2021Sep 30, 2021-$3.61M–
Q2 FY2021Jun 30, 2021-$3.52M–
Q1 FY2021Mar 31, 2021-$4.25M–
Q4 FY2020Dec 31, 2020-$1.72M–

More MiNK Therapeutics figures

See a number that looks wrong?